Tilatamig samrotecan
Tilatamig samrotecan (AZD9592) is an antibody-drug conjugate (ADC) used to deliver topoisomerase I inhibitors (TOP1i), targeting the epidermal growth factor receptor (EGFR) and c-MET, with anti-tumor activity. Tilatamig samrotecan (AZD9592) can induce DNA double-strand breaks, increase the expression of pRAD50 and γH2AX, and inhibit the growth of non-small cell lung cancer[1][2].
Product Specifications
Product Name Alternative
AZD9592
UNSPSC
12352203
Target
DNA/RNA Synthesis; Topoisomerase
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Tilatamigsamrotecan]
References & Citations
[1]Lara McGrath, et al. Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. Cancer research. (2023) 83 (7_Supplement) : 5737.|[2]Kinsley Wang, et al. Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions. Antibodies (Basel) . 2024 Oct 18;13 (4) :88.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
Phase 1
Isoform
Topo I
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
